» Articles » PMID: 19539984

A Thymic Stromal Lymphopoietin Gene Variant is Associated with Asthma and Airway Hyperresponsiveness

Overview
Date 2009 Jun 23
PMID 19539984
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The epithelial cell-derived protein thymic stromal lymphopoietin stimulates dendritic and mast cells to promote proallergic T(H)2 responses. Studies of transgenic expression of thymic stromal lymphopoietin and its receptor knockout mice have emphasized its critical role in the development of allergic inflammation. Association of genetic variation in thymic stromal lymphopoietin with IgE levels has been reported for human subjects.

Objective: The aim of this study was to evaluate the relationship between variants of thymic stromal lymphopoietin and asthma and related phenotypes.

Methods: We selected 6 single nucleotide polymorphisms in thymic stromal lymphopoietin and genotyped 5565 individuals from 4 independent asthma studies and tested for association with asthma, atopy, atopic asthma, and airway hyperresponsiveness by using a general allelic likelihood ratio test. P values were corrected for the effective number of independent single nucleotide polymorphisms and phenotypes.

Results: The A allele of rs1837253, which is 5.7 kb upstream of the transcription start site of the gene, was associated with protection from asthma, atopic asthma, and airway hyperresponsiveness, with the odds ratios and corrected P values for each being 0.79 and 0.0058; 0.75 and 0.0074; and 0.76 and 0.0094, respectively. Associations between thymic stromal lymphopoietin and asthma-related phenotypes were the most statistically significant observations in our study, which has to date examined 98 candidate genes. Full results are available online at http://genapha.icapture.ubc.ca/.

Conclusions: A genetic variant in the region of the thymic stromal lymphopoietin gene is associated with the phenotypes of asthma and airway hyperresponsiveness.

Citing Articles

variant may affect the response to type 2 biologics in patients with severe asthma.

Nishi K, Matsumoto H, Sunadome H, Nagasaki T, Oguma T, Tashima N ERJ Open Res. 2025; 11(1.

PMID: 39811553 PMC: 11726575. DOI: 10.1183/23120541.00448-2024.


Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps.

De Corso E, Hellings P, Fokkens W, Klimek L, Peters A, Scadding G Curr Allergy Asthma Rep. 2024; 25(1):7.

PMID: 39636450 DOI: 10.1007/s11882-024-01186-2.


From gene identifications to therapeutic targets for asthma: Focus on great potentials of , and .

Zhang Y Chin Med J Pulm Crit Care Med. 2024; 1(3):139-147.

PMID: 39171126 PMC: 11332877. DOI: 10.1016/j.pccm.2023.08.001.


Airway remodeling heterogeneity in asthma and its relationship to disease outcomes.

Hsieh A, Assadinia N, Hackett T Front Physiol. 2023; 14:1113100.

PMID: 36744026 PMC: 9892557. DOI: 10.3389/fphys.2023.1113100.


Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD.

Calderon A, Dimond C, Choy D, Pappu R, Grimbaldeston M, Mohan D Eur Respir Rev. 2023; 32(167).

PMID: 36697211 PMC: 9879340. DOI: 10.1183/16000617.0144-2022.